ObeEnd - Pioneering Drug-Free Weight Management Wristband

May 13, 2024 11:00 PM AEST | By Cision

ObeEnd - Pioneering Drug-Free Weight Management Wristband — Image source: Kalkine Media

Recent News

Electronic Arts raised by HSBC after strong quarter, MoffettNathanson...

3 Ways AI Accelerates Sustainability Efforts

How large could the compute demand for GenAI inference become? UBS dis...

Walt Disney shares gain 8% as earnings, outlook beat estimates

VANCOUVER, BC, May 13, 2024 /PRNewswire/ -- WAT Medical, a leader in innovative healthcare solutions, announces the development of ObeEnd, the world's first weight management wristband backed by clinical evidence showcasing its efficacy in reducing dietary intake. Findings from this groundbreaking study were presented at the Canadian Nutrition Society annual conference in May 2024.

According to the World Health Organization (WHO), the global prevalence of obesity has reached alarming proportions, affecting one in eight individuals worldwide. With 2.5 billion adults classified as overweight in 2022, a figure that has more than doubled since 1990, addressing this epidemic has become a paramount global health concern. The Centers for Disease Control and Prevention (CDC) has identified obesity as a prevalent, serious, and costly disease, linked to numerous debilitating conditions including heart disease, stroke, diabetes, and cancer, all of which contribute to premature mortality rates.

While medical interventions for weight loss exist, such as surgical procedures or pharmaceuticals like the FDA-approved Wegovy (semaglutide injection), these options often present significant drawbacks including adverse side effects, inconsistent outcomes, and challenges in sustaining weight loss post-treatment cessation. Studies have shown that discontinuing semaglutide injections can lead to rapid weight regain, underscoring the need for alternative solutions.

WAT Medical's mission is to offer a safe and effective alternative for weight management, and ObeEnd represents a paradigm shift in this pursuit. Leveraging neuromodulation technology, ObeEnd delivers targeted electrical impulses via PC6 to mitigate gastric secretion while enhancing post-exercise recovery. Clinical studies have demonstrated that ObeEnd results in significant reduction in caloric intake and pepsinogen-1 production. The mechanism underlying ObeEnd's efficacy is believed to be sympathetic inhibition, which have also demonstrated efficacy in alleviating symptoms of nausea, vomiting, and even reducing blood pressure levels.

The encouraging clinical results of ObeEnd mark a significant milestone towards the realization of an innovative, drug-free wearable solution for weight management. Ongoing clinical studies, conducted in collaboration with Concordia University, aim to further substantiate these findings, with additional data anticipated in the near future.

For further information on ObeEnd and WAT Medical's pioneering efforts in healthcare innovation, please visit watmedical.com.

References

[1] Rachel Abramczuk, Sarah Feola, Lyne Al-Nabelsi, and Sylvia Santosa. The effect of PC6 stimulation on dietary intake and appetite[J]. Applied Physiology, Nutrition, and Metabolism, 2024, 49: 20-21.

[2] https://www.who.int/news-room/fact-sheets/detail/obesity-and overweight#:~:text=Key%20facts,years%20and%20older)%20were%20overweight.

[3] https://www.cdc.gov/obesity/data/adult.html

[4] https://health.ucdavis.edu/blog/cultivating-health/ozempic-for-weight-loss-does-it-work-and-what-do-experts-recommend/2023/07#:~:text=However%2C%20semaglutide%20is%20approved%20for,it%2C%20establishing%20a%20new%20normal.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.